Clinical Trial Supplies Global Market Report 2024

The clinical trial supplies market size has grown strongly in recent years. It will grow from $2.52 billion in 2023 to $2.75 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The expansion observed in the historical period can be attributed to several factors. These include a heightened prevalence of chronic diseases, more stringent regulatory requirements, a growing demand for clinical trials aimed at developing new treatments, and the escalating complexity associated with conducting these trials.

The clinical trial supplies market size is expected to see strong growth in the next few years. It will grow to $3.72 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. During the forecast period, the anticipated growth can be linked to several key factors. These include the globalization of clinical trials, the broadening scope of cell and gene therapy trials, a heightened emphasis on patient-centric trials, the increasing presence of biologics and biosimilar drugs in trials, and the emergence of virtual and decentralized trials as prominent methodologies. Noteworthy trends expected in the forecast period encompass the integration of artificial intelligence (AI) and predictive analytics, the utilization of 3D printing, a heightened focus on sustainability and eco-friendliness in managing clinical trial supplies, augmented research and development investments by biopharmaceutical and pharmaceutical companies, and advancements in blockchain technology within the industry.

The clinical trial supplies market is poised for substantial growth, driven by the escalating number of registered clinical trials. These trials, essential for assessing the safety and efficacy of new medical treatments, interventions, and diagnostic procedures, rely on a range of supplies, including pharmaceuticals and medical devices. To illustrate, in May 2023, ClinicalTrials.gov reported a notable increase, with 437,533 registered clinical trials compared to 399,499 in 2022 across the United States and 221 countries. This surge in clinical trial registrations is a key factor fueling the expansion of the clinical trial supplies market, crucial for ensuring successful trials, accurate data collection, and patient safety.

The clinical trial supplies market is expected to experience significant growth, propelled by the expanding geriatric population. The term 'geriatric population' refers to individuals aged 65 and older, often dealing with multiple health conditions. This demographic shift creates a heightened demand for diverse and specialized trial supplies to support research and development efforts focused on age-related diseases. As of October 2022, a report from the World Health Organization projects that by 2030, one out of every six individuals globally will be 60 years old or older. By 2050, the number is expected to reach 2.1 billion. Consequently, the growing geriatric population plays a pivotal role in driving the clinical trial supplies market's growth.

A prominent trend shaping the landscape of the clinical trial supplies market is the adoption of advanced real-world evidence platforms. Leading companies in this market are embracing innovative technologies to revolutionize healthcare decision-making, drug development, and patient care. This strategic move involves harnessing real-world data to generate evidence-based insights. As an illustration, in April 2023, Komodo Health, a US-based healthcare technology company, introduced MapEnhance - an integrated real-world evidence technology platform. This platform, incorporating a network of specialty data partners, provides customers with a comprehensive perspective on clinical events and patient populations. MapEnhance includes precision molecular diagnostics, standard laboratory diagnostics, and electronic medical records, offering unparalleled insights for various therapeutic areas and hospital settings.

Major players in the clinical trial supplies market are actively investing in cutting-edge technologies, such as clinical development platforms, to broaden their customer base, drive sales, and enhance revenue. A clinical development platform serves as an integrated system or software facilitating the planning, management, execution, and monitoring of clinical trials and research studies. For instance, in June 2022, ZS Associates, a US-based management consulting and technology firm, launched the ZAIDYN Clinical Development platform. This platform stands out for its ability to break down silos in clinical trial design, overcome enrollment and engagement obstacles, and expedite product delivery to patients. ZAIDYN facilitates seamless global team collaboration, connecting products, processes, applications, algorithms, and data assets to provide potent insights influencing clinical research. Its compatibility with existing IT systems enhances efficiency and connectivity, reducing costs and empowering life sciences companies of all sizes to innovate and thrive in the evolving global healthcare ecosystem.

In December 2021, Thermo Fisher Scientific Inc., a prominent scientific research and laboratory services company based in the United States, completed the acquisition of PPD Inc. for a total of $17.4 billion. This strategic move was aimed at broadening Thermo Fisher's range of services throughout the entire clinical development journey. The expanded services now cover scientific discovery, assessment of safety and efficacy, evaluation of healthcare outcomes, management of trial logistics, and the development and production of therapeutics. PPD Inc. is recognized as a US-based provider of clinical research services and supplies for clinical studies.


Major companies operating in the clinical trial supplies market report are Thermo Fisher Scientific Inc., IQVIA, Eurofins Scientific SE, Parexel International Corporation, ICON PLC, Catalent Inc., Intertek Group PLC, Recipharm AB, World Courier, Almac Group Ltd., Piramal Pharma Solutions, Clinigen Group PLC, Movianto GmbH, Marken Limited, PCI Pharma Services, Rubicon Research Private Limited, Bionical Ltd., Durbin PLC, SIRO Clinpharm Pvt. Ltd., Biocair International Ltd., Ancillare LP., Myonex, Klifo A/S, Alium Medical Limited, ADAllen Pharma, Sharp Services LLC.

North America was the largest region in the clinical trial supplies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical trial supplies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical trial supplies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Essential services related to clinical trial supplies involve logistics and distribution, storage and retention, supply chain management, packaging, labeling, blinding manufacturing, and comparator sourcing. Logistics and distribution manage the movement of trial supplies from manufacturing facilities to trial sites, ensuring prompt availability and efficient delivery. These supplies are crucial across various clinical phases (Phase I to Phase IV) for treating conditions such as oncology, CNS disorders, cardiovascular ailments, infectious diseases, metabolic disorders, among others. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and medical device firms.

The clinical trial supplies research report is one of a series of new reports that provides clinical trial supplies market statistics, including the clinical trial supplies industry's global market size, regional shares, competitors with a clinical trial supplies market share, detailed clinical trial supplies market segments, market trends and opportunities, and any further data you may need to thrive in the clinical trial supplies industry. This clinical trial supplies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The clinical trial supplies market consists of revenues earned by entities by providing quality control, regulatory compliance, and return and destruction management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical trial supplies market also includes sales of investigational products, comparator products, and clinical trial kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.